Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Chengfeng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-9007-7637; OpenAlex author ID A5101515228. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers

Papers 9

  1. A CT-Based Deep Learning Radiomics Nomogram for Early Recurrence Prediction in Pancreatic Cancer: A Multicenter Study. Last author DOI 10.1245/s10434-025-17748-1↗
  2. ASO Author Reflections: Toward Precision Imaging: Preoperative Prediction of Early Recurrence in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17830-8↗
  3. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  4. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  5. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Co-author DOI 10.1007/s00280-018-3650-4↗
  6. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Co-author DOI 10.7150/thno.23978↗
  7. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Co-author DOI 10.1038/ng.3568↗
  8. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2012-303477↗
  9. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Co-author DOI 10.1038/ng.1020↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiao Guan · 2 shared papers, 2025 · strength 0.66
  2. Xu Che · 5 shared papers, 2011–2021 · strength 0.29
  3. Chen Hsuan Wu · 5 shared papers, 2011–2021 · strength 0.29
  4. Dongxin Lin · 5 shared papers, 2011–2021 · strength 0.29
  5. Jian Zheng · 4 shared papers, 2016–2021 · strength 0.28
  6. Xudong Huang · 3 shared papers, 2016–2021 · strength 0.21
  7. Yanfen Zheng · 2 shared papers, 2019–2021 · strength 0.16
  8. Zhixiang Zuo · 2 shared papers, 2019–2021 · strength 0.16
  9. Ying Ye · 2 shared papers, 2019–2021 · strength 0.16
  10. Jiachun Su · 2 shared papers, 2019–2021 · strength 0.16
  11. Jialiang Zhang · 2 shared papers, 2019–2021 · strength 0.16
  12. Ling Pan · 2 shared papers, 2019–2021 · strength 0.16
  13. Rufu Chen · 2 shared papers, 2019–2021 · strength 0.16
  14. Lusheng Wei · 1 shared paper, 2021 · strength 0.10
  15. Lingxing Zeng · 1 shared paper, 2021 · strength 0.10
  16. Guandi Wu · 1 shared paper, 2021 · strength 0.10
  17. Shaoping Zhang · 1 shared paper, 2021 · strength 0.10
  18. Junge Deng · 1 shared paper, 2021 · strength 0.10
  19. Wen Zhang · 1 shared paper, 2018 · strength 0.08
  20. Aiping Zhou · 1 shared paper, 2018 · strength 0.08
  21. Yongkun Sun · 1 shared paper, 2018 · strength 0.08
  22. Chunxia Du · 1 shared paper, 2018 · strength 0.08
  23. Yanjie Zhao · 1 shared paper, 2018 · strength 0.07
  24. Zhiqiang Fu · 1 shared paper, 2019 · strength 0.07
  25. Shengping Li · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.